Sera Prognostics, Inc. (SERA)
1.89
-0.02
(-1.05%)
USD |
NASDAQ |
Nov 19, 16:00
Sera Prognostics Cash from Operations (Quarterly) : -7.298M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -7.298M |
| June 30, 2026 | -6.311M |
| March 31, 2026 | -8.774M |
| December 31, 2025 | -6.12M |
| September 30, 2025 | -6.477M |
| June 30, 2025 | -5.473M |
| March 31, 2025 | -7.553M |
| December 31, 2024 | -6.26M |
| September 30, 2024 | -6.995M |
| June 30, 2024 | -5.928M |
| March 31, 2024 | 4.994M |
| December 31, 2023 | -6.765M |
| September 30, 2023 | -7.594M |
| June 30, 2023 | -7.948M |
| Date | Value |
|---|---|
| March 31, 2023 | -4.881M |
| December 31, 2022 | -7.238M |
| September 30, 2022 | -8.777M |
| June 30, 2022 | -9.038M |
| March 31, 2022 | -9.557M |
| December 31, 2021 | -9.152M |
| September 30, 2021 | -9.296M |
| June 30, 2021 | -6.238M |
| March 31, 2021 | -6.95M |
| December 31, 2020 | -4.185M |
| September 30, 2020 | -3.923M |
| June 30, 2020 | -4.145M |
| March 31, 2020 | -4.615M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Myriad Genetics, Inc. | -6.50M |
| BioRestorative Therapies, Inc. | -3.808M |
| CareDx, Inc. | 12.72M |
| Natera, Inc. | 43.93M |
| Exagen, Inc. | -2.575M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 6.838M |
| Cash from Financing (Quarterly) | 0.048M |
| Free Cash Flow | -29.03M |
| Free Cash Flow Per Share (Quarterly) | -0.1463 |
| Free Cash Flow to Equity (Quarterly) | -7.704M |
| Free Cash Flow to Firm (Quarterly) | -7.43M |
| Free Cash Flow Yield | -38.65% |